Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤ 35 years~* Male~* Healthy~Exclusion Criteria:~* Use of any medication.~* History of allergic reaction to dipyridamole~* Bleeding disorder.~* Smoking.~* Previous spontaneous vagal collapse.~* History, signs or symptoms of cardiovascular disease.~* Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block.~* Hypertension (defined as RR systolic \> 160 or RR diastolic \> 90).~* Hypotension (defined as RR systolic \< 100 or RR diastolic \< 50).~* Renal impairment (defined as plasma creatinin \>120 μmol/l).~* Liver enzyme abnormalities or positive hepatitis serology.~* Positive HIV serology or any other obvious disease associated with immune deficiency.~* Febrile illness in the week before the LPS challenge.~* Participation in another drug trial or donation of blood 3 months prior to the planned LPS challenge.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Endotoxemia placebo (Type: PLACEBO_COMPARATOR): Endotoxin combined with placebo
- Endotoxemia Dipyridamole (Type: EXPERIMENTAL): Endotoxin combined with Dipyridamol treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).